Hemodynamic Effects of Labetalol in Patients with Combined Hypertension and Left Ventricular Failure

Johnson, Lynne L.; Cubbon, Judith; Escala, Edith; Sciacca, Robert R.; Ramanathan, Kodangudi B.; Berger, Harvey J.; Jones, Robert H.

doi:10.1097/00005344-198809000-00014

Cited by 9 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…39 Labetalol has not been systematically investigated in heart failure populations but has been shown to improve myocardial function in subjects with hypertensive cardiomyopathy. 40 Another third-generation compound with limited but favorable experience 41,42 in heart failure trials is nebivolol, which is a markedly ␤ 1 -selective 43 compound whose vasodilatory action appears to be due to potentiation of nitric oxide. 44 Two other ␤-blockers with vasodilating activity, carvedilol and bucindolol, have been extensively evaluated in the treatment of chronic heart failure.…”

Section: Three Classes Of ␤-Blockers Available For Clinical Usementioning

confidence: 99%

β-Adrenergic Receptor Blockade in Chronic Heart Failure

2000

View full text Add to dashboard Cite

Section: Three Classes Of ␤-Blockers Available For Clinical Usementioning

confidence: 99%

β-Adrenergic Receptor Blockade in Chronic Heart Failure

2000

View full text Add to dashboard Cite

“…По всем этим точкам оценки эффективности были достоверно выявлены преимущества терапии β-блокаторами. Лишь в одном из исследований с применением соталола отмечено увеличение риска смерти от кардиоваскулярных заболеваний на 7%, что не позволяет применять соталол для терапии больных ХСН без дополнительных (аритмии) показаний [67][68][69].…”

Section: бета-адреноблокаторы при лечении хснunclassified

Rational Choice of Β-Adrenoblockers in Chronic Heart Failure Therapy

Максимов¹

2007

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Рациональный выбор β-адреноблокаторов при лечении хронической сердечной недостаточности М.Л. Максимов Московская медицинская академия им. И.М. Сеченова Представлены результаты исследований по применению β-адреноблокаторов при хронической сердечной недостаточности (ХСН) и собственные данные по изучению эффективности и переносимости небиволола у 113 больных ишемической болезнью сердца, осложненной ХСН. Подчеркивается, что терапия β-адреноблокаторами положительно влияет на сердечную гемодинамику и симптомы ХСН, значительно снижает риск смерти и частоту госпитализации больных. Применение β-адреноблокаторов показано при любой тяжести ХСН. При лечении ХСН показана эффективность метопролола, бисопролола и карведилола, а также небиволола у пожилых пациентов. Ключевые слова: хроническая сердечная недостаточность, β-адреноблокаторы, небиволол. РФК 2007; 1: 60-68 Rational choice of β-adrenoblockers in chronic heart failure therapy M.L. Maximov Moscow medical academy named after I.M. Setchenov There were presented results of clinical trials on β-adrenoblockers usage in patients with chronic heart failure (CHF) as well as data of own study on nebivolol efficacy and tolerability in 113 patients with ischemic heart disease, complicated with CHF. It is emphasized that therapy with βadrenoblockers positively influences on cardiac hemodynamics and CHF symptoms, significantly reduces mortality risk and the frequency of hospitalizations. The usage of β-adrenoblockers is indicated in CHF of any stage. Efficacy of metoprolol, bisoprolol and carvedilol had been proven in CHF therapy. Nebivolol was effective in elderly patients with CHF.

show abstract

“…Johnson et al [90] studied 16 patients with hypertension and a history of heart failure in an open trial. Patients were treated with digitalis and diuretics, and additional antihypertensive treatment was withdrawn before baseline studies.…”

Section: Labetalolmentioning

confidence: 99%

Beta receptor antagonists in the treatment of heart failure

Persson

Erhardt

1991

Cardiovasc Drug Ther

View full text Add to dashboard Cite

The use of beta-receptor antagonists in the treatment of heart failure is controversial. Available data do not allow general recommendations regarding their use. In dilated cardiomyopathy, several studies suggest that long-term treatment in individual patients reduces symptoms and increases exercise capacity. Short-term treatment is usually not beneficial, except in patients with ischemically induced left ventricular dysfunction. In heart failure, post myocardial infarction and in chronic ischemic heart disease, no proper long-term study has been performed to evaluate its effects. However, patients with acute myocardial infarction tolerate beta blockers, despite the presence of left ventricular dysfunction and long-term prognosis is improved. Newer agents, some with ancillary properties, such as intrinsic activity and vasodilatation, may have advantages. In the future we need a better description of the cardiac status in our patients in order to be able to select those that will respond favorably to beta-receptor antagonists. The mechanisms by which some patients improve are still obscure. Protection against receptor downregulation, restoration of receptor density, protection against cardiotoxicity of catecholamines, and improvement in ischemic systolic and diastolic left ventricular function are all possible. The fear that beta-receptor antagonists are dangerous in heart failure is in most instances not warranted, but an initial deterioration may have to be accepted in order to gain long-term beneficial effects. Ongoing studies in both idiopathic cardiomyopathy and in postinfarction failure will hopefully help us to define the use of beta-adrenoceptor antagonists in the future.

show abstract

Hemodynamic Effects of Labetalol in Patients with Combined Hypertension and Left Ventricular Failure

Cited by 9 publications

References 0 publications

β-Adrenergic Receptor Blockade in Chronic Heart Failure

β-Adrenergic Receptor Blockade in Chronic Heart Failure

Rational Choice of Β-Adrenoblockers in Chronic Heart Failure Therapy

Beta receptor antagonists in the treatment of heart failure

Contact Info

Product

Resources

About